Drug Approval | January 22, 2025
Kwality Pharmaceuticals receives SFDA GMP approval for 2 units
This certification will open new markets for the Kwality Pharma
This certification will open new markets for the Kwality Pharma
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
The company has paid an Interim Environmental Damage Compensation of Rs. 3.40 lakh to GPCB
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Hyper-automated AI is a unified framework combining AI, ML, RPA, and NLQ to streamline data extraction, quality management, transformation, and actionable insights - all on a single platform
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
Subscribe To Our Newsletter & Stay Updated
